Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07122700 · ClinicalTrials.gov registry record
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
A clinical trial of Cirrhosis, Liver and Liver Fibrosis, sponsored by Foundation for the National Institutes of Health.
- Recruiting
- Registry status
- 400
- Enrollment target
- 4
- Study locations
NCT07122700 is a study of Cirrhosis, Liver and Liver Fibrosis that is actively recruiting participants, run by Foundation for the National Institutes of Health. The registered enrollment target is 400 participants, above the 230-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (74% higher). The trial reports 4 study locations across 3 states.
The verdict
NCT07122700, a study of Cirrhosis, Liver and Liver Fibrosis, is actively recruiting participants, sponsored by Foundation for the National Institutes of Health.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 4
- Study locations
Study Summary
The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.
Conditions Studied
Study Locations (4)
Texas
- First Surgical Hospital - Bellaire
- Endeavor Clinical Trials - San Antonio
Florida
- Clinical Pharmacology of Miami - Miami
Ohio
- Ohio Clinical Trials - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2026-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07122700
The ClinicalTrials.gov registry entry for NCT07122700 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 230-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (74% higher). The listed sponsor is Foundation for the National Institutes of Health, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Cirrhosis, Liver appearing as the primary indexed condition, and to 0 interventions.
NCT07122700 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT07122700 about?
NCT07122700 is a clinical study titled "Evaluation of Non-Invasive Tests for Metabolic Liver Disease". The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (...
What is the current status of trial NCT07122700?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2025-05-13. Estimated completion is 2026-07-31.
What conditions does trial NCT07122700 study?
This clinical trial studies the following conditions: Cirrhosis, Liver, Liver Fibrosis, NASH, Liver Fat, Liver Steatoses.
Who is sponsoring clinical trial NCT07122700?
This trial is sponsored by Foundation for the National Institutes of Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07122700 being conducted?
This trial has 4 study locations across Florida, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
RECRUITING · Phase 1
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
-
Measuring Patient Reported Needs in Outpatient Liver Disease Management
RECRUITING
-
Molecular Mechanism of Exercise in Cirrhosis
RECRUITING · NA
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.